NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points<
14 Oct 2025

Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points

Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors
Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma<
09 Oct 2025

Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma

Fast Track designation underscores the potential for ADCE-D01 to address the high unmet clinical need in soft tissue sarcoma.
Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)<
07 Oct 2025

Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)

Neurona to provide an update on its unilateral and bilateral MTLE programs at the American Epilepsy Society’s Annual Meeting in December 2025

AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage<
02 Oct 2025

AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage

Top line data are expected in early 2026, and the full dataset will be presented thereafter at a scientific conference.
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia<
30 Sep 2025

Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia

Phase 2 trial seeks to establish proof-of-concept of KYN-5356; topline results are expected by Q4 2026
ReproNovo announces clinical trial approval notice for RPN-001 in China<
30 Sep 2025

ReproNovo announces clinical trial approval notice for RPN-001 in China

Key regulatory milestone in the global development of RPN‑001
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001<
25 Sep 2025

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001

Reduces cost and de-risks development of VMX-C001 in Japan
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health<
24 Sep 2025

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health

The studies established the lead asset SYT-510 to be well tolerated in healthy volunteers at all doses with a good safety profile
Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial<
24 Sep 2025

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment

Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer<
18 Sep 2025

Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer

Key findings include an estimated €105 million in savings over 10 years.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.